DAR Heads Into Earnings With a Valuation Gap and Growing Short Positions

Darling Ingredients reports its Q3 results on October 29 with the stock down roughly 10% over the past month and sitting almost 50% below the analyst consensus price target.

The gap between the current price and analyst views is the most striking feature of the setup. The stock closed at $55.46 on October 28. The consensus mean target is $81.83, implying roughly 48% upside. JP Morgan raised its target to $83 in mid-October while maintaining Overweight. UBS lifted its target to $88 in September, also holding Buy. Barclays is the outlier, initiating Equal-Weight in June with a $58 target and nudging it higher since. The bulls and bears are not really arguing about direction. They are arguing about timing and margin recovery: the bull case rests on improving rendering margins and rising tallow demand, while Barclays' more cautious stance reflects uncertainty around sustainable aviation fuel policy and compressed near-term earnings growth. The 90-day forward EPS momentum score ranks in the 96th percentile, a strong reading, but the 12-month forward EPS year-on-year growth score ranks just 19th percentile, pointing to an earnings profile that has yet to fully recover.

Short positioning has been rising recently but does not look aggressive in absolute terms. Short interest climbed about 4.5% over the past week to 3.6% of the free float. That is up from a monthly low following a sharp drop in early October, when shorts fell from around 6.7 million to 5.4 million shares in a matter of days. The borrow market offers no constraint for new shorts: availability is deeply loose at over 6,000% of short interest, meaning there are vastly more shares available to lend than are currently borrowed. Cost to borrow is 0.41%, negligible. The ORTEX short score of 34 is middling, consistent with a stock that has some short interest but no meaningful squeeze pressure.

Options positioning has turned slightly more defensive since mid-October. The put/call ratio moved from around 0.46 in early October to 0.56 now, near the 52-week high of 0.59. It is modestly above its 20-day average of 0.52, though the z-score of 0.74 falls well short of the kind of extreme reading that would signal real fear. The one noteworthy data point from the alt data layer is a Wikipedia and ORTEX page-view signal showing retail attention at a z-score of 3.1 as of October 22, well above the company's own 90-day history. That reflects heightened interest rather than any directional signal, and the dataset has not been measured to lead Darling's reported figures.

CEO Randall Stuewe sold 5,000 shares at $68.20 in early September, after two further open-market sales in August at prices between $63 and $65. None were executed under a 10b5-1 plan. Combined with other executive sales, the net insider transaction value over the past 90 days was roughly negative $2.1 million. Insiders were selling into prices well above where the stock trades today. The print will test whether the fundamental improvement that analysts have been pricing into their targets has actually begun to materialise in the numbers.